Both were over-the-counter continuous glucose monitors (CGM) that would monitor the rise and fall of my glucose levels.

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

Citi analyst Joanne Wuensch reiterated a Buy rating on Dexcom today and set a price target of $84.00. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc.

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.